From Yahoo Finance: 2025-05-28 13:13:00

Barclays analyst Andrew Mok raised Privia Health Group Inc. (PRVA) price target to $24 from $23, citing steady progress in Q1 2025 with outperformance in fee-for-service business. The company reported a 12.8% year-over-year increase in Practice Collections, reaching $798.6 million, leading to a 35.1% rise in Adjusted EBITDA to $26.9 million.

Privia Health’s strategic expansion includes a $95 million transaction for IMS in Arizona, expected to be EBITDA positive by Q4 2025, supporting fee-for-service operations. The company collaborates with physician practices, health plans, and health systems, offering technology and population health tools. Barclays maintains an Equal Weight rating on PRVA shares.

While PRVA shows growth potential, some AI stocks may offer higher returns with limited downside risk. For those seeking a promising AI stock with 100x upside potential, consider alternatives. Check out the report on the cheapest AI stock for more information. No disclosure mentioned.

Read more: Barclays Raises Privia Health (PRVA) PT to $24 on Strong Q1 Fee-for-Service Performance